Last reviewed · How we verify
Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders (KASPR)
The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in women with hypothalamic amenorrhea (HA). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Kisspeptin will be administered subcutaneously (SC) for two weeks in a pulsatile fashion. Ultrasound monitoring of ovarian follicular growth and frequent blood sampling (every 10 minutes for up to two hours) will be performed to assess the physiologic response to kisspeptin over time.
Details
| Lead sponsor | Stephanie B. Seminara, MD |
|---|---|
| Phase | PHASE1 |
| Status | COMPLETED |
| Enrolment | 13 |
| Start date | Fri Dec 16 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sun Aug 31 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Hypothalamic Amenorrhea
- Hypogonadotropic Hypogonadism
Interventions
- Kisspeptin 112-121
Countries
United States